Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection

Abstract

Although immunodeficiency is usually considered a prerequisite of oncogenesis, a detailed immune profile in cancer has not yet been described. Without such profiling, it is not surprising that there is a vast discrepancy in the responses of cancer patients to immunotherapy. Our results show that the integrity of the immune system deteriorates with cancer progression by displaying a trend toward decreasing levels of functional T cells, including CD4, naïve, and central memory T cells, and an expansion of hyporesponsive populations such as CD28− and CMV-specific T cells. One hundred and one patients constitute the study group for the observational study reported in this paper. Forty-eight patients with newly diagnosed stages III and IV and 53 patients with extensively treated stage IV disease. The costimulatory molecules CD27 and CD28 were downregulated in all patients. Among the proinflammatory cytokines (IL-6, TNF-α, IFN-γ), only IL-6 differed significantly among the groups, increasing as the cancer stage progressed. Plasma IL-7 did not differ among the participants. The relative deficits of naïve T cells in cancer patients may be associated with the downregulation of IL-7Rα expression rather than changes in the circulating levels of IL-7. The downregulation of IL-7Rα expression was shown to be associated with increased levels of intracellular CMV. The present study suggests that the immune impairment in patients with cancer is associated with multiple factors, such as the stage of cancer, consequence of CMV infection and impact of treatment.

DOI: 10.1007/s00262-009-0753-0

9 Figures and Tables

0102030201520162017
Citations per Year

Citation Velocity: 8

Averaging 8 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Chen2009ImmuneII, title={Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection}, author={I-Hsuan Chen and Yuen-Liang Lai and Chien Liang Wu and Yi-Fang Chang and Chen-Chung Chu and I-Fang Tsai and Fang-ju Sun and Yen-Ta Lu}, journal={Cancer Immunology, Immunotherapy}, year={2009}, volume={59}, pages={323-334} }